Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPOX | P50336 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8660425 | 0.84 | ROCK2 (0.47) | PPOXADORA3ROCK2CA9 | |
| SCHEMBL8661584 | 0.80 | PPOX (0.58) | PPOXOPRM1 | |
| SCHEMBL29349639 | 0.80 | PPOX (0.58) | PPOXOPRM1 | |
| SCHEMBL6658377 | 0.79 | PPOX (0.51) | PPOX | |
| SCHEMBL29576004 | 0.79 | PPOX (0.51) | PPOX | |
| SCHEMBL30274423 | 0.76 | PPOX (0.57) | PPOXOPRM1 | |
| SCHEMBL9120418 | 0.76 | PPOX (0.57) | PPOXOPRM1 | |
| SCHEMBL10562068 | 0.75 | ROCK2 (0.47) | PPOXROCK2 | |
| SCHEMBL9427767 | 0.74 | PPOX (0.44) | PPOXKMT2AADORA3 | |
| SCHEMBL29575421 | 0.74 | PPOX (0.44) | PPOXKMT2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115850195-A | Synthetic method of sulfentrazone intermediate | 宁夏格瑞精细化工有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-8669371-B2 | Regioselective chlorination of the phenyl ring of 4,5-dihydro-1-phenyl-1H-1,2,4-triazol-5-ones | TAGROS CHEMICALS INDIA PVT LTD (IN) | 2014-03-11 | — | — | US | disclosed |
| US-20130072689-A1 | Regioselective chlorination of the phenyl ring of 4,5-dihydro-1-phenyl-1H-1,2,4-triazol-5-ones | TAGROS CHEMICALS INDIA, LTD. (IN) | 2013-03-21 | — | — | US | disclosed |
| EP-1115711-B1 | REGIOSELECTIVE FLUORINATION OF PHENYL-SUBSTITUTED TRIAZOLINONES | FMC CORP (US) | 2003-06-04 | — | — | EP | disclosed |
| US-20020156321-A1 | Continuous preparation of high purity Bis(fluoroxy)difluoromethane (BDM) at elevated pressure | VERSUM MATERIALS US, LLC | 2002-10-24 | — | — | US | disclosed |
| EP-1115711-A1 | REGIOSELECTIVE FLUORINATION OF PHENYL-SUBSTITUTED TRIAZOLINONES | FMC CORPORATION (US) | 2001-07-18 | — | — | EP | disclosed |
| US-6218545-B1 | Regioselective fluorination of phenyl-substituted triazolinones | FMC CORPORATION | 2001-04-17 | — | — | US | disclosed |
| WO-2000012490-A1 | REGIOSELECTIVE FLUORINATION OF PHENYL-SUBSTITUTED TRIAZOLINONES | FMC CORPORATION (US) | 2000-03-09 | — | — | WO | disclosed |
| US-5468868-A | Process for the selective chlorination of 4,5-dihydro-1-phenyl-1H-1,2,4-triazol-5-one | FMC CORPORATION (US) | 1995-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156321-A1 | Continuous preparation of high purity Bis(fluoroxy)difluoromethane (BDM) at elevated pressure | FOS, PBRM1, NEFM | PPOX 164/4885NPC1 1176/4885GAA 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.